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Amodel of hematopoietic developmentwherein
multipotentiality is conserved until segregation
of myeloid and lymphoid potential has recently
been challenged, proposing that megakaryo-
cyte/erythrocyte (MegE) potential is lost in
Flk2/Flt3-expressing early progenitors. Here,
we used sensitive in vivo approaches to quanti-
tatively and kinetically assess the MegE poten-
tial of hematopoietic stem cells and various
Flk2+ early progenitors and compared it with
the MegE potential of downstream committed
myeloid and lymphoid progenitors and with
their ability to give rise to mature myelomono-
cytic and lymphoid cells. We demonstrate that
Flk2+ early progenitors retain MegE potential in
vivo both at the population and clonal levels.
These results indicate that Flk2 expression by
early progenitors is not at the expense of full
multipotency and support the current model of
hematopoietic development with segregation
of myeloid and lymphoid lineages from multi-
potent progenitors.
INTRODUCTION
Hematopoietic development is one of the most intensely
studied systems of cellular differentiation, where multipo-
tent self-renewing hematopoietic stem cells (HSC) give
rise to a hierarchy of progenitor populations with more
restricted lineage potential, ultimately leading to the pro-
duction of all types of mature blood cells. Prospective
isolation of cellular subsets based on expression of cell-
surface markers followed by functional characterization
using in vitro and in vivo assays has provided key insights
into hematopoietic development (Weissman, 2000). Onemodel states that only the most primitive long-term recon-
stituting subset of HSC (LT-HSC) self-renew for life and
give rise to short-term reconstituting subsets of HSC
(ST-HSC), with limited self-renewal activity, and then to
multipotent progenitors (MPP) that do not self-renew
(Spangrude et al., 1988; Morrison et al., 1997; Christensen
and Weissman, 2001). In this model, differentiation prog-
resses with segregation of myeloid and lymphoid lineages
through the generation of common myeloid progenitors
(CMP) (Akashi et al., 2000) and common lymphoid progen-
itors (CLP) (Kondo et al., 1997). Both CLP and CMP un-
dergo further lineage segregation, with CMP giving rise
to myelomonocytic progenitors (GMP) and megakaryo-
cyte/erythrocyte progenitors (MEP) that separate granulo-
cyte and macrophage production from red blood cell and
platelet production (Akashi et al., 2000).
In the mouse, multipotent hematopoietic activity is con-
tained in a small fraction of the bone marrow that lacks
expression of mature hematolymphoid-associated cell-
surface markers (lineage or ‘‘Lin’’ markers) and displays
high levels of the stem cell-associated markers c-Kit and
Sca-1 (Lin/c-Kit+/Sca-1+ or ‘‘KLS’’) (Spangrude et al.,
1988; Ikuta and Weissman, 1992). The KLS fraction can
be further subdivided into functionally distinct subpopula-
tions based on the expression levels of the Thy1.1
(Spangrude et al., 1988), CD4 and Mac-1 (Morrison and
Weissman, 1994), CD34 (Osawa et al., 1996), Flk2/Flt3
(Adolfsson et al., 2001; Christensen and Weissman,
2001), and the Slam family (Kiel et al., 2005; Forsberg
et al., 2005) of surface molecules. Within the KLS fraction,
loss of Thy1.1 and gain of Flk2 expression correlates with
decreased self-renewal ability (Adolfsson et al., 2001;
Christensen and Weissman, 2001) and increased proli-
feration (Passegue´ et al., 2005). Recently, it has been
reported that Flk2-expressing KLS cells might not be
fully multipotent because they failed to generate signifi-
cant megakaryocyte (Meg) and erythrocyte (E) progenies
in the assays used in those studies (Yang et al., 2005;
Adolfsson et al., 2005). Conclusions from those reportsCell 126, 415–426, July 28, 2006 ª2006 Elsevier Inc. 415
challenged the current fate map of hematopoietic devel-
opment and the existence of MPP and CMP populations
by suggesting that early progenitor populations might se-
quentially lose lineage potential as they differentiate from
LT-HSC, starting with loss of MegE potential (Adolfsson
et al., 2005; also see commentaries by Akashi et al.,
2005; Hock and Orkin, 2005).
An important test for HSC function is their ability to
reconstitute the blood system of an irradiated host, includ-
ing the HSC pool. Commonly, donor cells are distin-
guished from host cells by transplantation of purified pop-
ulations into conditioned hosts with an allelic difference in
the hematopoietic cell-surface marker CD45, followed by
allele-specific antibody labeling (Spangrude et al., 1988).
While all mature myelomonocytic and lymphoid cells ex-
press robust CD45 levels, mature cells of the MegE line-
age lack CD45 expression, making it difficult to assess
directly whether the transplanted cells are capable of
forming platelets and red blood cells in vivo. Furthermore,
while single-cell assessment of lineage potential is feasi-
ble for LT-HSC (Smith et al., 1991; Wagers et al., 2002;
Osawa et al., 1996; Adolfsson et al., 2001), progenitors
with lower self-renewal potential give rise to insufficient
numbers of progeny for robust single-cell detection
in vivo. Thus, as self-renewal ability declines, increasing
numbers of input cells are needed to allow detection of
progeny. In addition, mature myeloid cells are short lived
(days), while a significant fraction of mature lymphocytes
are long lived (months to years), enabling easier detection
of lymphoid versus myeloerythroid progeny at late time
points. Together, these limitations have made it difficult to
assess in vivo the full lineage potential of early progenitor
cells.
Here, we have used sensitive in vivo approaches to
quantitatively and kinetically assay the MegE potential
of the KLS fraction of mouse bone marrow, divided
into LT-HSC (Thy1.1int/Flk2 KLS), short-term HSC
(ST-HSCF: Thy1.1int/Flk2+ KLS), multipotent progenitor
population (MPPF: Thy1.1/Flk2+ KLS) (Christensen and
Weissman, 2001), or ‘‘lymphoid-primed’’ multipotent pro-
genitors (LMPP: 25% brightest Flk2+ KLS) (Adolfsson
et al., 2005), and compared it with the MegE potential of
downstream myeloid (CMP, GMP, and MEP) and lym-
phoid (CLP) progenitors and with their ability to give rise
to mature myelomonocytic and lymphoid cells in vivo.
We demonstrate that Flk2+ ST-HSCF, MPPF, and LMPP
retain MegE potential at the population and clonal levels
in vivo, readily detectable when sufficient numbers of
input cells are provided and when progeny are investi-
gated at the early and late time points. We also estab-
lished the timecourse of mature cell production by each
of these progenitor populations, hence providing the tim-
ing required for these early differentiation events in vivo.
These results demonstrate that Flk2 expression is not at
the expense of full multipotency and support the current
model of hematopoietic development with segregation
of myeloid and lymphoid lineages from multipotent
progenitors.416 Cell 126, 415–426, July 28, 2006 ª2006 Elsevier Inc.RESULTS
Tracking the Lineage Potential of Stem
and Progenitor Cells
Due to differences in self-renewal ability and proliferation
rates, stem and progenitor cells differ considerably in their
ability to expand both in vitro and in vivo. To assay the
expansion capacity of LT-HSC, ST-HSCF, MPPF, CMP,
GMP, and MEP in vitro, cells were grown in liquid media
containing cytokines and growth factors promoting mye-
loerythroid proliferation and differentiation (Figure 1A).
For the first 4 days of culture, MPPF displayed the greatest
rate of expansion, while by days 6 and 8 ST-HSCF and
LT-HSC, respectively, accumulated to a larger extent.
Among the myeloid progenitors, CMP displayed a kinetics
of expansion very similar to MPPF, while GMP and MEP
proliferated poorly throughout the culture period. After
8 days, LT-HSC had undergone an expansion of 1600-
fold, ST-HSCF of 1200-fold, MPPF of 350-fold, CMP
of 250-fold, MEP of 81-fold, and GMP of 65-fold.
These results indicate an inverse correlation between
the burst size of each progenitor population and its degree
of maturation, which has to be taken into account when
investigating lineage potential in vivo. The differentiation
potential of each population was also investigated at the
single-cell level in methylcellulose media and further con-
firmed the direct correlation between the time course of
differentiation and the developmental stage of the starting
population (Figure S1).
To circumvent the lack of CD45 expression by mature
cells of the MegE lineage, we used b-actin GFP transgenic
mice (Wright et al., 2001) as a source of donor cells and
transplanted purified stem and progenitor populations at
various doses into sublethally irradiated (475 rad) con-
genic wild-type recipient mice (Figure 1B). For all experi-
ments cells were double or triple sorted to ensure
maximum purity. Since all platelets (Plt) (Nakorn et al.,
2003) and nucleated myelomonocytic and lymphoid cells
in the peripheral blood (PB) of b-actin GFP mice are
positive for GFP (Figures 1C and 1D), this assay enabled
direct and quantitative in vivo tracking of mature cell pro-
duction by each transplanted population. The use of sub-
lethal irradiation, as opposed to lethal irradiation, allowed
us to follow the kinetics of mature cell production with
high resolution, starting within days after transplantation.
Platelet Production
To determine whether Flk2 expression identifies a KLS
population lacking MegE potential, we purified in parallel
LT-HSC, ST-HSCF, MPPF (Christensen and Weissman,
2001), and LMPP (Adolfsson et al., 2005) from b-actin
GFP mice (Figure 2A). The relationship between these
populations is shown in Figure S2. At 12 days posttrans-
plantation, LT-HSC provided the highest levels of GFP+
Plt at every cell dose transplanted (Figure 2B). Although
with lower efficiency than equivalent numbers of
LT-HSC, ST-HSCF, MPPF, and LMPP produced robust,
dose-dependent numbers of GFP+ Plt. Importantly, Plt
production from those Flk2+ KLS cells was more efficient
than from equivalent numbers of myeloid committed pro-
genitors CMP/MEP isolated and transplanted together.
Neither GMP nor CLP, even used at the highest cell
dose tested (10,000 cells), gave rise to any detectable
Plt (Figures 2B and S3). These results demonstrate that
ST-HSCF, MPPF, and LMPP are capable of thrombopoie-
sis in vivo but require higher cell doses than LT-HSC, al-
though lower than CMP/MEP, to provide robust platelet
Figure 1. Experimental Strategy Used to Investigate the Line-
age Potential of Stem and Progenitor Cells
(A) Comparison between the burst size of LT-HSC, Flk2+ early progen-
itors (ST-HSCF, MPPF) and committed myeloid progenitors (CMP,
GMP, and MEP) in liquid culture. Five hundred purified cells were
seeded in IMDM media containing SCF, Flt3-L, IL-11, IL-3, Tpo, Epo,
and GM-CSF, and total numbers of live cells were counted after the
indicated days of culture.
(B) Schematic representation of the in vivo tracking strategy used to in-
vestigate lineage potentials of stem and progenitor cells. Donor cells
are purified from b-actin GFP mice and transplanted at various cell
doses into sublethally irradiated (475 rad) wild-type recipient. Trans-
planted mice are bled at frequent intervals to follow with high resolution
the kinetics of lineage repopulation in the peripheral blood (PB).
(C) FACS analysis of PB platelets (Plt) defined as FSClow/Gr-1/Ter-
119/CD61+ cells, illustrating that 100% of them are GFP+ in b-actin
GFP mice.
(D) FACS analysis of PB nucleated cells (Ter-119), illustrating that
100% of them are GFP+ in b-actin GFP mice. GFP+ nucleated cells
can be further subdivided into myelomonocytic cells (Gr-1/Mac-1+)
and lymphoid B220+ B cells or TCR-b+ T cells.Figure 2. Platelet Production by Stem and Progenitor Cells
In Vivo
(A) Gating strategies used to purify LT-HSC, ST-HSCF, MPPF, and
LMPP from c-Kit-enriched b-actin GFP transgenic C57Bl/6-Thy1.1
mouse bone marrow.
(B) Dose dependency of donor-derived platelet production. FACS
analysis at 12 days posttransplantation of GFP+ donor-derived Plt
present in the PB of sublethally irradiated mice transplanted with the
indicated doses for each subpopulation (k = 103 cells).Cell 126, 415–426, July 28, 2006 ª2006 Elsevier Inc. 417
Figure 3. Multilineage Differentiation
Kinetics of Stem and Progenitor Cells
In Vivo
(A) Quantitative and kinetic analysis of GFP+
donor-derived Plt production in PB of suble-
thally irradiated mice transplanted with the indi-
cated doses for each subpopulation (n = 5 per
subset and cell dose, k = 103 cells). Plt genera-
tion from MPPF, LMPP, and CMP/MEP are
compared on a logarithmic scale for clarity
(bottom graph).
(B) Quantitative and kinetic analysis of GFP+
donor-derived nucleated cell production in PB
of the same mice as in (A). The two bottom
graphs show the contribution of Gr-1/Mac-1+
and B220+ cells as percent of total donor-
derived cells. The shaded area indicates back-
ground detection level. Results are expressed
as average ± standard deviation (error bars).
(C) FACS analysis of total GFP+ donor-derived
nucleated cells, and its further subdivision into
myeloid (Gr-1/Mac-1) and lymphoid (B220/
TCR-b) components, in the PB of mice trans-
planted with 500 LT-HSC, MPPF, or LMPP at
day 16 (top panels) and day 28 (bottom panels)
posttransplantation.contribution, consistent with their more limited expansion
capacities.
Kinetics of Mature Cell Production
To establish the kinetics of mature cell production from
each population, we followed over time the production
of donor-derived Plt and nucleated Gr-1/Mac-1+ myelo-
monocytes, B220+ B cells, and TCR-b+ T cells in the PB
of the transplanted animals (Figures 3 and S3). Donor-
derived Plt were first detected at 7–9 days for all trans-
planted populations, with Plt production from LT-HSC
increasing over a 30-day period and then remaining
stable (Figure 3A). In contrast, Plt production from
ST-HSCF, MPPF, and LMPP peaked at days 16–20 and
then declined, resulting in gradually decreasing levels of
ST-HSCF-derived Plt over a period of 3 months, while
MPPF- and LMPP-derived Plt reached undetectable
levels by 4 weeks posttransplantation. Importantly,
CMP/MEP-derived Plt production was optimal at day 9418 Cell 126, 415–426, July 28, 2006 ª2006 Elsevier Inc.and disappeared within 16 to 28 days for every cell dose
tested (Figure 3A).
LT-HSC were the only cells able to provide sustained
production of multilineage donor-derived nucleated cells,
which emerged in the PB around day 12 and continued to
increase beyond 1 month posttransplantation. In contrast,
all progenitor populations produced a transient wave of
mature cells, which depended on for its amplitude, emer-
gence, and disappearance time the differentiation stage
of the input population and on the type of mature cell pro-
duced (short-lived myeloid cells or long-lived lymphoid
cells) (Figures 3B, 3C and S3). Hence, ST-HSCF-derived
cells emerged by day 9 and reached a plateau by days
16–20 before gradually declining, while both MPPF and
LMPP-derived cells emerged (day 7) and peaked (days
12–16) a few days earlier before declining. In all cases,
myelomonocytic maturation occurred first (Figure 3B).
While LT-HSC, and to a lower extent ST-HSCF, sustained
durable production of myelomonocytic cells, production
from MPPF and LMPP rapidly declined, reaching unde-
tectable levels within4 weeks posttransplantation, a tim-
ing matching Plt disappearance in the same animals
(Figure 3A). Myelomonocytic cells derived from trans-
planted CMP/MEP (peaking at day 12) and GMP (peaking
at day 9) also did not accumulate and disappeared within
16 to 20 days (Figures 3B and S3). Donor-derived B cells
emerged in the PB of MPPF- and LMPP-transplanted
mice around day 9, while ST-HSCF required 16 days
and LT-HSC 20 days for significant B lymphocyte pro-
duction. T cell emergence also occurred earlier from
transplanted MPPF and LMPP compared to LT-HSC and
ST-HSCF (24–28 days versus 40–49 days). From trans-
planted CLP, donor-derived B cells emerged as early as
day 7 and increased until the emergence of T cells by
day 20, before gradually declining without detectable my-
eloid readout (Figure S3). Lymphopoiesis, like myelopoie-
sis, was not sustained in progenitor-transplanted mice,
but in contrast to short-lived myeloid cells, long-lived lym-
phoid cells persisted for several months in these animals,
although with declining levels.
Mature red blood cells (RBC) from b-actin GFP trans-
genic mice do not express GFP, hence precluding direct
analysis of donor contribution to mature erythrocytes.
However, immature erythrocyte precursors (FSChigh/
CD45int/Gr-1/Mac-1/CD71+/Ter-119+) (Socolovsky et al.,
2001) in the bone marrow (BM) and spleen (Sp) of these
mice express low levels of GFP (Figure 4A). At day 16 post-
transplantation, both BM and Sp populations of GFPdull
donor-derived erythrocyte precursors were observed in
mice transplanted either with 500 LT-HSC, ST-HSCF,
MPPF, or LMPP and were absent from mice transplanted
with either 10,000 GMP (data not shown) or CLP
(Figure 4B). While these erythrocyte precursors stably
persisted in LT-HSC- and, for shorter times, ST-HSCF-
transplanted mice, they were only transiently found in
MPPF-and LMPP-transplanted mice and disappeared by
day 49 (Figure S4). Together, these results demonstrate
that Flk2+ KLS cells are fully multipotent and have MegE
potential in vivo, readily detectable when sufficient num-
bers of input cells are provided and when progeny are
investigated at the proper time points. They also indicate
that on a cell-by-cell basis ST-HSCF, MPPF, and LMPP
are less efficient than LT-HSC in producing every type of
mature cell, including B and T lymphocytes, consistent
with their more advanced maturation stage.
Erythrocyte Production from Clonogenic Cells
To investigate directly the ability of Flk2+ ST-HSCF, MPPF,
and LMPP to give rise to erythrocytes in vivo, we used
conventional spleen colony-forming-unit (CFU-S) assays
in lethally irradiated mice. Similar to previous results (Na
Nakorn et al., 2002), only mice transplanted with 500
CMP/MEP had visible CFU-S by day 8 (1/24 frequency),
while mice transplanted with 500 GMP did not develop
spleen colonies at any time point (Figure 5A). Mice trans-
planted with 100 LT-HSC or ST-HSCF had no obvious
CFU-S until day 12 (1/33 and 1/18 frequencies, re-spectively), while mice transplanted with either 100 or
500 MPPF or 500 LMPP had by day 10 readily detectable
CFU-S, which were more numerous and larger by day 12
(Figure 5A and data not shown). MPPF gave rise to CFU-S
with a frequency of 1/78 and LMPP with a frequency
of 1/230 in our assay, which is below the frequency of
1/85 previously reported for this population at day 11
(Yang et al., 2005). The lower frequency of CFU-S in
LMPP than in MPPF could represent lower efficiency of
spleen homing by clonogenic precursors, or higher het-
erogeneity in the LMPP population with some precursors
failing to produce detectable myelo-erythroid spleen colo-
nies. Flow cytometric analysis of splenocytes after RBC
lysis indicated the presence of numerous Ter-119+ cells,
either GFP (nucleated erythrocytes) or GFPdull (erythrocyte
precursors), in every spleen harboring CFU-S (Figure 5B).
Such cells were absent from spleens of lethally irradiated
nontransplanted control mice, demonstrating that nucle-
ated Ter-119+ cells are of donor origin despite the lack
of GFP expression. Immunofluorescence analysis of day
12 spleen sections showed large CFU-S colonies, all con-
taining nucleated Ter-119+ cells interspersed with donor-
derived GFP+ cells, consistent with the clonal origin of the
cells within a colony (Figure S5). Radioprotection analysis
also indicates that ST-HSCF radioprotected as efficiently
as LT-HSC at the 500 cell dose, while MPPF and LMPP,
though with decreasing potency, were more efficient
than CMP/MEP at providing radioprotection (Figure S6).
Together, these results demonstrate that Flk2+ KLS cells
are capable of robust erythropoiesis and megakaryopoie-
sis in vivo both at the population and clonal levels.
Short-Term Repopulation Kinetics
We also followed the emergence of GFP+ donor-derived
cells in the BM, Sp, and PB of the lethally irradiated
mice transplanted with 100 LT-HSC or ST-HSCF and
500 MPPF or CMP/MEP used for the CFU-S assays. At
day 8, LT-HSC-transplanted mice only showed the pres-
ence of low numbers of GFP+ cells in the BM, while
ST-HSCF-transplanted mice displayed GFP+ cells in
both BM and PB, and MPPF-transplanted mice had even
higher numbers of GFP+ cells in all three compartments
(Figure 5C). At this time, CMP/MEP-transplanted mice
already displayed large numbers of GFPdull nucleated
erythrocytes in the Sp but very few GFP+ cells in the BM
and the PB. By day 10, the readout from LT-HSC-trans-
planted mice was very similar to day 8 ST-HSCF, with
GFP+ cells only in the BM and PB, while the readout of
ST-HSCF-transplanted animals closely resembled day 8
MPPF except for higher numbers of donor-derived cells
generated. At this time, MPPF-transplanted mice dis-
played massive expansion of GFP+ cells in all three
compartments and appearance of GFPdull nucleated ery-
throcytes in the Sp, which correlate with the early emer-
gence of CFU-S in this population (Figure 5A). At day 12,
all three populations showed expansion of donor-derived
cells in all compartments and presence of large numbers
of GFPdull nucleated erythrocytes in the Sp. Together,Cell 126, 415–426, July 28, 2006 ª2006 Elsevier Inc. 419
Figure 4. Generation of Erythrocyte Precursors from Stem and Progenitor Cells In Vivo
(A) Erythrocyte precursor analysis in bone marrow (BM) and spleen (Sp) of b-actin GFP mice. Gating strategy used for the FACS analysis and sorting of
FSChigh/CD45int/GFPdull/Gr-1/Mac-1/CD71+/Ter-119+ erythrocyte precursor subsets. Shown are May-Gru¨nwald-Giemsa stains confirming imma-
ture erythrocyte precursor morphology in purified subsets.
(B) Erythrocyte precursor generation in transplanted mice. Sublethally irradiated (475 rad) mice were transplanted with either 500 LT-HSC, ST-HSCF,
MPPF, and LMPP or 10,000 CLP purified from b-actin GFP transgenic mice and analyzed at day 16 posttransplantation for the presence of erythrocyte
precursors in the BM and Sp. The numbers indicate percentages of total live cells.these observations suggest that LT-HSC need2 days to
produce a ST-HSCF-equivalent readout, which required
1–2 days more to give rise to an MPPF-equivalent read-420 Cell 126, 415–426, July 28, 2006 ª2006 Elsevier Inc.out and then another day for a CMP/MEP-equivalent
readout, thereby providing an estimate of 4 days for
transit through the KLS pool.
Figure 5. Erythroid Cell Production and Short-Term Kinetics of Repopulation
(A) CFU-S assay. Spleens of mice transplanted with either no cells (control) or the indicated populations (*100/500 cells) were isolated at days 8, 10,
and 12 post-lethal irradiation (950 rad) and visually inspected for presence of macroscopic colonies before or after fixation in Tellyesniczky’s solution
(TF). The frequency of CFU-S [1/(numbers of injected cells divided by numbers of observed spleen colonies)] is given at day 8 for CMP/MEP and day
12 for LT-HSC, ST-HSCF, MPPF, and LMPP. n.d.: not determined; d.: dead.
(B) Generation of nucleated erythrocytes. FACS analysis (after RBC lysis) of day 12 untransplanted (no cells) and MPPF-transplanted spleens showing
Ter-119 levels in live nucleated Gr-1/Mac-1 cells separated into three subsets based on GFP expression levels. Note that all Ter-119+ cells in MPPF
spleen are GFP negative to dull and are absent in control spleen. The overlay histogram (right side) compares Ter-119 levels by Gr-1/Mac-1 live
cells (regardless of GFP expression) in spleen of mice transplanted with the indicated populations.
(C) FACS analysis following over time the production of total GFP+ donor-derived cells in the bone marrow (BM), spleen (Sp), and peripheral blood
(PB) in mice from (A). The boxes give the percentages of GFP+ and GFPdull donor-derived cells.EpoR, TpoR, and IL3R Gene Expression
We then analyzed these populations by quantitative RT-
PCR for the expression levels of the two major receptors
associated with MegE development: the erythropoietin
receptor (EpoR) and the thrombopoietin receptor (TpoR)
(Figure 6). The highest levels of EpoR mRNA expressionwere found in MEP, with LT-HSC displaying an 5-fold
lower level, similar to levels reported in CMP (Terskikh
et al., 2003). Although expressed at lower levels than in
LT-HSC, EpoR mRNA was detectable in ST-HSCF (14-
fold lower), MPPF (45-fold lower), and LMPP (65-fold
lower) and to levels much higher than in populations thatCell 126, 415–426, July 28, 2006 ª2006 Elsevier Inc. 421
Figure 6. Multipotency and Expression of the MegE and GM Differentiation Gene Programs
(A) Real-time quantitative RT-PCR analysis (qRT-PCR) for erythropoietin receptor (EpoR), thrombopoietin receptor (TpoR), and b-actin mRNA expres-
sion levels in LT-HSC (gray), ST-HSCF (orange), MPPF (red), LMPP (black), MEP (magenta), and Gr-1+/Mac-1+ granulocytes (light blue) and B220+
splenic B lymphocytes (green).
(B) Fold differences. Summary of the qRT-PCR analysis of EpoR, TpoR, and interleukin-3 receptor (IL3R) mRNA expression. Each value has been
standardized for b-actin expression levels and the relative expression level of each gene for each subpopulation is expressed as fold differences com-
pared to the levels detected in LT-HSC (set to 0). Results are given as the average from two to three independent experiments. nd: not detectable.did not undergo MegE differentiation such as mature
granulocytes (220-fold lower) and B lymphocytes (unde-
tectable). In agreement with previous reports, LT-HSC ex-
pressed TpoR mRNA at higher levels than MEP (Terskikh
et al., 2003). While slightly decreased in ST-HSCF (3-fold
lower), MPPF (5-fold lower), and LMPP (7-fold lower)
compared to LT-HSC, TpoR expression was much higher
in those populations than in granulocytes (700-fold
lower) and B lymphocytes (undetectable). Similarly,
ST-HSCF, MPPF, and LMPP expressed higher levels of
GM-associated receptors IL3R, GM-CSFR, G-CSFR,
and M-CSFR than mature cell populations, even to slightly
higher levels than in LT-HSC (Figure 6B and data not
shown). Together, these results indicate that Flk2+ KLS
cells express at the population level the appropriate
myeloid gene programs to undergo both MegE and GM
differentiation, and while the transcript levels of some
of the MegE regulators are lower than in LT-HSC, they
appear to be sufficient for their in vivo MegE potential.
DISCUSSION
A thorough understanding of the lineage potential of each
subset of hematopoietic stem and progenitor populations
is critical in establishing an accurate map of cell-fate de-
termination during hematopoietic development. A contro-
versy exists as to whether multipotentiality is conserved
until segregation of myeloid and lymphoid potential, or
whether progenitor populations sequentially lose lineage
potential when differentiating from LT-HSC, starting with422 Cell 126, 415–426, July 28, 2006 ª2006 Elsevier Inc.loss of MegE potential. Here, we demonstrate that multi-
potentiality is retained in the Flk2/Flt3-positive KLS frac-
tion, and that loss of lineage potential occurs later during
differentiation into the oligolineage-committed progenitor
populations. Moreover, by uncovering differences in the
timecourse of mature cell production from LT-HSC and
progenitor cells, we provide a temporal component that
is of critical importance for the investigation of the lineage
potential of these populations in vivo and for comparing
findings between laboratories (Figure 7).
Our results differ from those of the Jacobsen group who
concluded that the 25% brightest Flk2+ KLS cells (LMPP)
lack MegE potential (Adolfsson et al., 2005). It is unlikely
that the difference in the assessed ability of LMPP to pro-
duce erythrocytes and platelets is due to subtle variations
in mouse strains or in sorting strategies, as the Jacobsen
group previously reported erythroid readout from LMPP in
CFU-S assays (Yang et al., 2005). Rather, we believe that
this discrepancy is due to several important differences in
the interpretation of the results and in experimental de-
sign, such as the choice of cell doses and timing for the
in vitro and in vivo analyses. To obtain a comprehensive
assessment of mature cell production in vivo, we com-
pared the engraftment levels of multiple progenitor popu-
lations with different lineage potential and burst sizes and
titrated the cell dose required to detect their mature prog-
enies. We found a direct correlation between the number
of cells needed and the maturation stage of the starting
population, indicating that engraftment and lineage poten-
tial of progenitor cells have to be investigated with greater
Figure 7. Kinetics of Blood Lineage Development
As LT-HSC differentiate into ST-HSCF and then to MPPF, they progressively lose their self-renewal ability, increase their proliferation, and change their
gene expression programs to leave the stem cell niche and undergo lineage differentiation while remaining multipotent. Within this scheme, LMPP
represent a more committed subset of MPPF. We estimated the duration of the transit through the KLS pool to be 4 days. The simultaneous emer-
gence of B lymphocytes and Gr, MF, and Plt as soon as 7 days posttransplantation of MPPF indicates that generation of CLP and CMP, and the further
separation of CMP into GMP and MEP, occurs with similar kinetics. The accumulation of Plt for up to 16 days, the maturation of nucleated E after 12
days, and the progressive increase in B cell production likely result from differences in proliferation rates of GMP, MEP, and CLP (Passegue´ et al.,
2005). The late emergence of T lymphocytes may relate to obligatory maturation steps in the thymus before release in the PB. Without constant
resupply from self-renewing LT-HSC, MPPF or LMPP production of short-lived Gr, MF and Plt become exhausted within a month while long-lived
T and B lymphocytes accumulate and persist for several months. Gr: granulocytes; MF: macrophages; Plt: platelets; E: erythrocytes; B: B lympho-
cytes; T: T lymphocytes.cell numbers than LT-HSC. Furthermore, without constant
resupply, as for the self-renewing LT-HSC, all mature cells
derived from progenitors were exhausted with kinetics
that directly depended on the half-life of the mature cells.
We found that short-lived myelomonocytic cells, platelets,
and erythrocyte progenitors disappear within 1 month
posttransplantation, while long-lived lymphoid cells that
can give rise to self-renewing progeny (such as memory
T and B cells) accumulate and persist for several months.
Thus, in contrast to LT-HSC, investigation of lineage po-
tential of progenitor cells has to be performed at several
distinct time points to allow optimal detection of their
progenies (before 3 weeks for myelopoiesis, after 3 weeks
for lymphopoiesis).
By isolating stem and progenitor cells from b-actin GFP
transgenic mice and by transplanting them at various cell
doses into sublethally irradiated mice, we were able to
track directly all donor-derived cells (including platelets
and erythrocyte precursors, with the exception of RBC)
and to follow with high resolution their kinetics of produc-
tion, starting within days after transplantation. Using this
sensitive approach, we demonstrate that Flk2+ ST-HSCF,
MPPF, and LMPP have robust MegE potential in vivo
and produce more mature cells of the MegE lineage than
committed myeloid progenitors CMP/MEP, as expectedfrom more primitive cells located developmentally up-
stream of these progenitors. Also as expected, we found
that Flk2+ KLS cells have lower MegE potential than
LT-HSC on a cell-by-cell basis, which was considered
the result of contamination by low numbers of LT-HSC
in the report by Adolfsson et al. (2005). By investigating
the MegE potential of these progenitors within a develop-
mental series (including both less [LT-HSC] and more
[CMP/MEP] committed progenitors), we show that this
readout indicates true MegE potential from a low burst
size population. We ruled out contamination by using
highly purified, double or triple sorted populations for all
of our assays. While very low numbers of contaminating
LT-HSC could be detected in ST-HSCF (<1/800 cells on
average), no contaminating LT-HSC or ST-HSCF were
observed in MPPF or LMPP by reanalysis of the sorted
populations (Figure S7). The differences observed for all
of the investigated populations in repopulating kinetics
(emergence, peak, and disappearance) also make con-
tamination an unreasonable explanation for our results.
Furthermore, the ability of ST-HSCF, MPPF, and LMPP
(Yang et al., 2005) to form CFU-S shows that erythropoietic
output is a constant feature of these populations. This also
ruled out the possibility that rare-contaminating LT-HSC
provide the erythropoietic readout as MPPF, LMPP, andCell 126, 415–426, July 28, 2006 ª2006 Elsevier Inc. 423
CMP/MEP (an unlikely contaminant) are the only popula-
tions with CFU-S at day 10. ST-HSCF, MPPF, and LMPP
also provide radioprotection following lethal irradiation at
a much lower cell dose than CMP/MEP, thereby emphasiz-
ing the robustness of their MegE potential in vivo. Then, we
are left with the question: what are the LMPP? They are
multipotent (at least at the population level), they represent
1/3 of the total MPPF population (Figure S2), and they
have lower burst size and overall lineage production than
MPPF. Based on these results, we conclude that a signifi-
cant proportion of them are a more mature subset of MPPF
that are still located developmentally upstream of CMP
and CLP (Figure 7). It is yet to be determined whether
they are heterogeneous and include a subset of more
committed lymphoid precursors that lack CFU-S activity,
and if so, whether at the clonal level such precursors retain
myelomonocytic potential yet have lost MegE potential.
As we show here that Flk2+ KLS cells are fully multipo-
tent, Flk2 expression per se does not appear to be a
marker of lymphoid commitment. Flk2+ KLS cells are pro-
miscuous in terms of gene expression at the population
level and coexpress, though at different levels, master
transcriptional regulators, signaling molecules, and cell-
surface receptors that are known to be specific for and/
or to specify myeloid or lymphoid fates (Forsberg et al.,
2005). This type of promiscuous gene expression might
be a defining characteristic of multipotency (Miyamoto
et al., 2002). However, it is possible that Flk2 signaling
facilitates lymphoid differentiation prior to commitment
to the lymphoid lineage, which is then clearly marked by
cell-surface expression of the interleukin-7 receptor
(IL7R) (Kondo et al., 1997). This would be consistent with
the phenotype of Flk2 null mice, which have defects pri-
marily in lymphoid cell development but also in myeloid
reconstitution (Mackarehtschian et al., 1995). In aged
wild-type mice, KLS cells have defective (but not absent)
lymphoid potential upon transplantation and a correlative
defect in the numbers of Flk2+ KLS cells (Rossi et al.,
2005). As there are lineage preferences, even at the level
of the LT-HSC, during ontogeny (Ikuta et al., 1990; Cu-
mano and Godin, 2001) and aging (Rossi et al., 2005), it
is possible that Flk2+ hematopoietic progenitors readout
lineage preferences rather than lineage exclusions; how-
ever, this is difficult to assess as production of different
types of mature progeny peak at distinct time points. It
is interesting to note that 500 transplanted MPPF or
LMPP produced GFP+ donor-derived cells in the same
range as 10,000 transplanted CMP/MEP at day 9 (myeloid
readout) and 10,000 transplanted CLP at day 20 (lymphoid
readout) (Figure S3), suggesting that about equal numbers
of CMP and CLP are generated from Flk2+ KLS at the pop-
ulation level. Hence, the proposed ‘‘lymphoid preference’’
of Flk2+ KLS cells may mainly reflect easier detection and/
or accumulation of their relatively long-lived lymphoid
progeny. A better understanding of Flk2 function in lym-
phoid differentiation and fate determination will require
further investigation of the activation level of Flk2 signaling
pathways downstream of the receptor. Separation of424 Cell 126, 415–426, July 28, 2006 ª2006 Elsevier Inc.Flk2+ multipotent progenitors with additional surface
markers, such as VCAM1 as recently reported (Forsberg
et al., 2005; Lai et al., 2005), will also be needed to appre-
ciate how lineage segregation and/or lineage exclusion
occurs from these multipotent cells.
We and others have previously described KLS subsets
of stem and multipotent cells with different marker combi-
nations (Osawa et al., 1996; Goodell et al., 1996; Morrison
et al., 1997; Ivanova et al., 2002), and the relationships be-
tween those populations and the ones described here
have not yet been fully investigated. Thus, there are a vari-
ety of multipotent cells from which progeny could undergo
lineage segregation into lymphoid and myeloid pathways.
Some latent but normally unused lineage plasticity re-
mains at these early stages of lineage commitment as
CLP, pro-T, and some early pro-B cells are able to revert
to myeloid fates upon specific transgene expression and
transcription factor inactivation or overexpression (Nutt
et al., 1999; Kondo et al., 2000; King et al., 2002; Xie
et al., 2004). CMP also display low B cell production
in vivo (Akashi et al., 2000; Figure S3), but further subdivi-
sion of this population with additional surface markers,
such as Flk2 (D’Amico and Wu, 2003; Nutt et al., 2005),
should provide a refined phenotypic definition of these
progenitors. Importantly, we never observed MegE poten-
tial without GM potential and vice versa from any of the
progenitor populations investigated (except from MEP
and GMP), indicating that segregation of MegE and GM
potential mainly occurs downstream of the CMP stage
as shown previously (Akashi et al., 2000).
As erythropoiesis (in contrast to lymphopoiesis) is indis-
pensable for the survival of the animal, it is possible that
multiple mechanisms exist for rapid production of MegE
cells and that LT-HSC give rise to mature RBC and plate-
lets without first differentiating through some or all of the
progenitor intermediates. Although this is an important
question, we are not aware of assays that allow a rigorous
assessment of this possibility in vivo. The kinetics of line-
age repopulation in both sublethally and lethally irradiated
mice argues, at least, for differentiation occurring with se-
quential maturation. In addition, we found a direct correla-
tion between the degree of commitment of the progenitor
cells and their rapidity to give rise to mature myelomono-
cytic, B and T cells. The only exception to this temporal
pattern is the simultaneous detection of platelets from all
the populations with MegE potential. We are currently un-
able to determine whether this is due to ‘‘short-cutting’’
through differentiation steps as proposed by others
(Takano et al., 2004); to lack of sensitivity of our assay in
detecting very small numbers of donor-derived platelets
at earlier time points when the levels of host-derived
platelets are still high; to differential responses to signals
mediating the response to irradiation; or to differential
trafficking to niches supporting megakaryopoiesis. Future
technical developments allowing the imaging of LT-HSC
cell division and subsequent determination of cell fate
will be needed to test these alternative models. As the im-
mediate microenvironment plays critical roles in cell-fate
determination, to address these questions it will be im-
portant to continue to improve the ability to determine
the localization of stem and progenitor cells both under
steady-state conditions (Kiel et al., 2005) and upon trans-
plantation (Cao et al., 2004).
In conclusion, our results support a model of hemato-
poietic development with segregation of myeloid and
lymphoid lineage potential from multipotent progenitors
(Figure 7). This model is, by definition, a simplification of
complex biological processes, but at the moment it does
account for most, if not all, of the differentiation events.
It tolerates hematopoietic plasticity in lineage segregation
at early stages of commitment, and it accommodates
intrinsic lineage preferences during ontogeny and aging.
This model will likely evolve further when as of yet un-
solved issues and critical questions will be addressed
through technical advances allowing the in vivo analysis
of clonal progeny for all progenitors, the in vivo tracking
of early differentiation events, the identification and char-
acterization of the niches where HSC and progenitors dif-
ferentiate, and the analysis at the single-cell instead of
population level of lineage priming and fate determination.
EXPERIMENTAL PROCEDURES
Mice
Four- to eight-week-old b-actin GFP C57Bl/6-Thy1.1 transgenic mice
(Wright et al., 2001) were used as donors and 8- to 10-week-old con-
genic C57Bl/6 wild-type mice were used as recipients. All mice were
maintained in Stanford University’s Research Animal Facility in accor-
dance with Stanford University guidelines.
Flow Cytometry
Staining and enrichment procedures for LT-HSC, ST-HSCF, MPPF,
LMPP, CMP, GMP, MEP, and CLP cell sorting and platelet analyses
were performed as previously described (Akashi et al., 2000; Christen-
sen and Weissman, 2001; Nakorn et al., 2003; Adolfsson et al., 2005).
Further information on cell preparation and staining procedures can be
found in Table S1. Cell sorting from b-actin GFP C57Bl/6-Thy1.1 trans-
genic mice was performed on a modified three-laser (488 nm argon,
598 nm dye, 407 nm Krypton) MoFlo hybrid controlled by digital Diva
electronics (Cytomation, Becton Dickinson). Each subpopulation
was either double or triple sorted and reanalyzed to ensure maximum
purity. Donor-derived GFP+ cells were analyzed on a two-laser (488 nm
argon, 633 nm HeNe) LSR1A (Becton Dickinson). PB GFP+ Plt were
analyzed using a gain of 8 and a threshold of 0 for the FSC channel.
In Vivo Assays
Transplantations were performed by retro-orbital injection of purified
cells. Recipient mice were either sublethally irradiated (475 rad) or
lethally irradiated (950 rad, delivered in split dose 3 hr apart) using an
X-ray source irradiator and given antibiotic-containing water for at
least 6 weeks postirradiation. PB was obtained from tail vein bleeding
and collected either into K2EDTA-coated collection tubes (Becton
Dickinson) for blood parameter analysis or in 4 ml of ACK (150 mM
NH4Cl/10 mM KHCO3) containing 10 mM EDTA for flow cytometry
analysis. Complete blood counts were done using a CELL-DYN 3500
analyzer (Abbot Diagnostic) calibrated for mouse blood samples.
CFU-S assays were performed as described (Morrison and Weissman,
1994) and spleens were fixed in Tellyesniczky’s solution (4 parts water:
13 ethanol: 2 formaldehyde: 1 glacial acetic acid) to count the nodules.
CFU-S per cell population is given as frequency 1/(numbers of injected
cells divided by numbers of observed spleen colonies).In Vitro Assays
For proliferation analysis, cells were cultured in Iscove’s modified Dul-
becco’s media (IMDM) containing 10% FCS, 13 penicillin/streptomycin,
2 mM GlutaMax-1, 0.1 mM nonessential amino acid, 1 mM sodium pyru-
vate, 50 mM 2-mercaptoethanol and supplemented with SCF (25 ng/ml),
Flt3 ligand (25 ng/ml), IL-11 (25 ng/ml), IL-3 (10 ng/ml), Tpo (25 ng/ml),
Epo (2.5 U/ml), and GM-CSF (10 ng/ml) (all purchased from Peprotech
and R & D). At the indicated time point, aliquots were sampled to count
the total number of live cells capable of excluding trypan blue.
Gene Expression Analysis
Total RNA was isolated using Trizol reagent (InVitrogen) from equivalent
numbers of cells, digested with DNaseI to remove DNA contamination,
and used for reverse-transcription according to the manufacturer’s in-
structions (SuperScript II kit, InVitrogen). QRT-PCR primers were de-
signed using Primer Express software (Applied Biosystems): EpoR
(fwd: GGC AGG AGG GAC ACA AAG G; rev: GCA GGT TGC TCA
GAA CAC ACT CA), TpoR (fwd: CAA CCA CTC CTA CCT ACC ACT
AAG C; rev: AGG AAT GTA TAG GTC TGC AGT AGC A), IL3R (fwd:
TGT CTC CAT CCC CCA CTT CTG; rev GGG TAA ACC TCT GAC
CTC GAC TTG), and b-actin (fwd: GAC GGC CAA GTC ATC ACT ATT
G; rev: GAC GGC CAG GTC ATC ACT ATT G). All reactions were per-
formed in an ABI-7000 sequence detection system using SYBR Green
PCR Core reagents and cDNA equivalent of300 cells per reaction as
previously described (Forsberg et al., 2005). Expression of the b-actin
gene was used to normalize the amount of the investigated transcript.
Supplemental Data
Supplemental Data include experimental procedures, seven figures,
and one table and can be found with this article online at http://
www.cell.com/cgi/content/full/126/2/415/DC1/.
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